BOPI 09 BR/2023 REPERTOIRE NUMERIQUE 33 (11) 21165 (51) A01N 25/00 (2018.01); A01N 25/02 (2018.01); A01N 25/14 (2018.01); A01N 43/00 (2018.01); A01N 47/02 (2018.01) ; A01P 7/00 (2018.01) (21) 1202300042 - PCT/IB2021/057351 (22) 10/08/2021 (30) IN n° 202021034295 du 10/08/2020 (54) A method for controlling insect pests in cotton. (72) BHOGE, Satish Ekanath (IN); SARAPH, Sanjay (IN) et NAGANUR, Sunil (IN) (73) UPL LIMITED, UPL House, 610 B/2, Off Western Express Highway, Bandra Village, Bandra (East), Maharashtra, MUMBAI 400051 (IN) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) The present disclosure relates to a method for the control of phytopathogenic insects. More particularly, the present disclosure relates to a method of using insecticides for the control of one or more insects in cotton plant. Consulter le mémoire ________________________________________ (11) 21166 (51) A61K 31/4439 (2018.01); A61P 11/00 (2018.01) ; C07D 413/04 (2018.01) (21) 1202300043 - PCT/US2021/044895 (22) 06/08/2021 (30) US n° 63/063, 194 du 07/08/2020 (54) Modulators of cystic fibrosis transmembrane conductance regulator. (72) MILLER, Mark Thomas (US); CLEVELAND, Thomas (US); ZHOU, Jinglan (US); BAEK, Minson (US); PARASELLI, Prasuna (US); CLEMENS, Jeremy, J. (US); BOOKSER, Brett C. (US); BECHARA, William Schulz (US); COON, Timothy R. (US); GALLANT, Michel (US); MADIDA RUAH, Sara Sabina (US); LATERREUR, Julie (US); MELILLO, Vito (US); RAMTOHUL, Yeeman K. (US); REDDY, Thumkunta Jagadeeswar (US); STURINO, Claudio (US) et VALDEZ, Lino (US) (73) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, BOSTON, Massachusetts 02210 (US) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS Sarl, The House of Gideon, Golf/Bastos Quarter, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators. Fig. 3 Consulter le mémoire
RkJQdWJsaXNoZXIy MTM1NDc3MA==